X4 touts more pos­i­tive PhI­II da­ta for its WHIM syn­drome treat­ment

X4 Phar­ma­ceu­ti­cals lift­ed the veil on more pos­i­tive da­ta from its Phase III study of ma­vorix­afor as a treat­ment of WHIM syn­drome, a rare im­mun­od­e­fi­cien­cy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER